Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL)
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL)
:
first analysis of a prospective multicenter phase-II-trial (T-PLL2) conducted by the German CLL study group (GCLLSG)